Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192398 · ClinicalTrials.gov registry record · NA
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02192398: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02192398 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02192398, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
Primary Outcome
Changes in numeric pain score (as indicated in Outcome Measure Title) will be used to compare the 3 treatment groups.
Interventions
- DRUG Placebo
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-10 |
| Phase | NA |
Why NCT02192398 stopped before completion
NCT02192398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02192398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02192398 about?
NCT02192398 is a clinical study titled "Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)". Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
What is the current status of trial NCT02192398?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2014-09. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02192398?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT02192398?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02192398's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia